📊 Chart of the Day: Viking Therapeutics (VKTX)
It may be time to take another look at Viking Therapeutics (NASDAQ: VKTX).
Currently trading around $27.50, VKTX could be setting up for another explosive move—driven largely by progress in its obesity drug pipeline and renewed acquisition speculation.
💉 Obesity Trials Fuel the Bull Case
Viking recently launched its VANQUISH Phase 3 clinical program for VK2735, a dual agonist targeting both GLP-1 and GIP receptors—important mechanisms in weight-loss therapy.
The company is advancing both oral and subcutaneous formulations, expanding the potential reach of the treatment.
According to CEO Brian Lian, Ph.D.:
“Along with the successful initiation of the Phase 3 program, we continue to make progress on VK2735’s broader development… We expect to report results of the Phase 2 VENTURE-Oral Dosing study in the second half of this year.”
🧬 Rumors of a Buyout?
There’s also speculation that Pfizer (PFE) could be eyeing Viking as a strategic acquisition target.
PFE CEO Albert Bourla recently stated the company is actively pursuing obesity-focused biotech partnerships to strengthen its pipeline. With VKTX’s promising clinical progress, it remains a name worth watching.
📈 Why VKTX Has Trader Attention
With the obesity drug race heating up—and VKTX showing momentum both fundamentally and technically—it’s a stock that deserves a spot on your watchlist.
Whether you’re trading short-term breakouts or looking for longer-term biotech exposure, VKTX has the potential to deliver in both categories.
👤 About Ian Cooper
Ian Cooper is a seasoned trader who uses a blend of technical, fundamental, and news-based analysis to identify high-probability opportunities. His premium options strategies are designed for active traders looking to grow their wealth with precision and discipline.